何琳琳,李 琴,刘定远,胡 波,李 莉.双嘧达莫辅助治疗川崎病患儿的疗效及对T淋巴细胞亚群、凝血功能影响[J].,2020,(10):1929-1932 |
双嘧达莫辅助治疗川崎病患儿的疗效及对T淋巴细胞亚群、凝血功能影响 |
Effect of Dipyridamole on T lymphocyte Subsets and Coagulation Function in Children with Kawasaki Disease |
投稿时间:2019-11-27 修订日期:2019-12-23 |
DOI:10.13241/j.cnki.pmb.2020.10.029 |
中文关键词: 双嘧达莫 丙种球蛋白 川崎病 T淋巴细胞亚群 凝血功能 辅助治疗 |
英文关键词: Dipyridamole Gamma globulin Kawasaki disease T lymphocyte subsets Coagulation function Adjuvant therapy |
基金项目:四川省卫生厅科研基金资助项目(120427) |
|
摘要点击次数: 676 |
全文下载次数: 360 |
中文摘要: |
摘要 目的:探讨双嘧达莫辅助治疗川崎病患儿的疗效及对T淋巴细胞亚群、凝血功能影响。方法:选择我院2016年3月至2018年1月接诊的90例川崎病患儿,通过随机数表法分为对照组44例和观察组46例,对照组给予常规治疗,观察组在对照组基础上联合双嘧达莫进行辅助治疗。两组患者均连续治疗8周。比较两组T淋巴细胞亚群、症状缓解情况、凝血功能的变化情况及并发症。结果:治疗后,观察组临床疗效总有效率高于对照组,差异均有统计学意义(P<0.05);观察组CD3+、CD8+均高于对照组,CD4+/CD8+低于对照组,差异均有统计学意义(P<0.05);观察组发热、颈淋巴结肿胀、眼结膜充血、口腔黏膜充血、躯干红斑缓解时间均短于对照组(P<0.05),差异均有统计学意义(P<0.05);观察组凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)均长于对照组,纤维蛋白原(FIB)低于对照组,差异均有统计学意义(P<0.05);两组不良反应、冠状动脉损害情况发生率比较差异无统计学意义(P>0.05)。结论:双嘧达莫辅助治疗川崎病患儿临床疗效显著,缩短患儿症状缓解时间,能有效调节T淋巴细胞亚群的表达及凝血功能,值得临床应用推广。 |
英文摘要: |
ABSTRACT Objective: To study effect of dipyridamole on T lymphocyte subsets and coagulation function in children with Kawasaki disease. Methods: 90 patients of Kawasaki disease in our hospital from March 2016 to January 2018 were selected and divided into control group 44 cases and observation group 46 cases by random number table. the control group was treated with conventional therapy, while the observation group was treated with dipyridamole on the basis of the control group. two groups of patients were treated continuously for 8 weeks. The T lymphocyte subsets, symptoms relief, changes of coagulation function and complications were compared between the two groups. Results: After treatment, the total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05); the levels of serum CD3+ and CD8+ in the observation group were higher than those in the control group, and the levels of CD4+/CD8+ in the observation group were lower than those in the control group, and the difference was statistically significant(P<0.05); the remission time of clinical symptoms such as body fever, cervical lymph node swelling, conjunctival congestion, oral mucosal hyperemia and erythema of trunk in the observation group was shorter than that in the control group, and the difference was statistically significant(P<0.05); the prothrombin time(PT) and activated partial thromboplastin time (APTT) in the observation group were longer than those in the control group, while the fibrinogen(FIB) were lower than those in the control group, and the difference was statistically significant(P<0.05); there was no significant difference in the incidence of adverse reactions and coronary artery lesions between the two groups(P>0.05). Conclusion: The clinical effect of dipyridamole in the adjuvant treatment of children with Kawasaki disease is remarkable. It can shorten the remission time of symptoms, effectively regulate the expression of T lymphocyte subsets and coagulation function. It is worthy of clinical application and promotion. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |